KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Inclusion Criteria * Male or female, ≥18 years * Pathologically confirmed diagnosis of thymic carcinoma * Inoperable or metastatic disease * Had failed at least one regimen containing platinum-based combination chemotherapy for locally advanced unresectable or metastatic disease * Baseline measurable disease Exclusion Criteria * Thymomas, thymolipoma, germ cell tumors, teratomas, seminomas * Leptomeningeal metastasis or untreated active CNS (central nervous system) metastasis or leptomeningeal metastasis. * Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks * Has received other anti-tumor treatment within 4 weeks * Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment * Curative radiation within 3 months of the first dose of trial treatment. * Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment